- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Compass Therapeutics to Participate in Upcoming Investor Events | 1 | GlobeNewswire (USA) | ||
| 12.11. | Compass Therapeutics GAAP EPS of -$0.08 | 1 | Seeking Alpha | ||
| 12.11. | Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update | 79 | GlobeNewswire (Europe) | Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first... ► Artikel lesen | |
| 12.11. | Compass Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11. | Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 69 | GlobeNewswire (Europe) | New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive... ► Artikel lesen | |
| 04.10. | Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.09. | Compass Therapeutics to Participate in Upcoming Investor Events | 1 | GlobeNewswire (USA) | ||
| COMPASS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.08. | Compass Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 12.08. | Compass Therapeutics GAAP EPS of -$0.10, revenue of $0.85M | 1 | Seeking Alpha | ||
| 12.08. | Compass Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 17.06. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 28.05. | Compass Therapeutics names Thomas Schuetz as CEO | 1 | Seeking Alpha | ||
| 28.05. | Compass Therapeutics Announces CEO Transition | 132 | GlobeNewswire (Europe) | BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics... ► Artikel lesen | |
| 28.05. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting | 173 | GlobeNewswire (Europe) | Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition... ► Artikel lesen | |
| 21.03. | Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update | 144 | GlobeNewswire (Europe) | Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line... ► Artikel lesen | |
| 05.01. | Compass Therapeutics Provides Corporate Update | 512 | GlobeNewswire (Europe) | We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,190 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,500 | -2,94 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 22,690 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
COMPASS THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,375 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COMPASS THERAPEUTICS INC finden Sie auf Wallstreet Online.
